hotspot -WSS

hotspot

author：fashion 2025-09-06 04:37:12 - browse：1

gantenerumab Alzheimer's disease Roche — Sebastien Bozon/AFP via Getty Images

LONDON — Roche on Thursday said its recently acquired experimental obesity medication helped people lose a significant amount of weight in an early trial, sending its shares up in early trading.

The drug, a once-weekly injection known as CT-388, resulted in an average placebo-adjusted weight loss of 18.8% after 24 weeks, the company said. The study was a Phase 1 trial, though it was placebo-controlled.

The reaction to such an early result — Roche shares were up roughly 4% early Thursday — is a signal both of the stakes of the obesity medication race and the keen interest investors have in the field.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Biogen walks away from Aduhelm, years after polarizing approval

focus

knowledge

WSS

The Affordable Care Act has saved billions in health care costs

Ionis has late

Why Medicare shouldn’t cover every FDA

Bernie Sanders is gearing up to subpoena pharma CEOs

Merck, Johnson & Johnson CEOs will testify on high drug prices

Cigna to pay $172 million to settle Medicare Advantage fraud probe

focus

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

focus

Apple is now the first public company to be valued at $3 trillion

Inequities make cancer less preventable for women: report

Virginia high school admissions case could be legal follow

How one patient went off dialysis — and others can too

As demand for Covid shots wanes, Moderna seeks its next success

How one patient went off dialysis — and others can too

Affirmative action in medical school literally saved lives

Why do women spend more than men on medical expenses?

Cancer drug shortages should be causing more outrage

Would Medicare drug price negotiations stall in a shutdown?

hotspot

How generative AI ratchets up security threats for health systems

Why do women spend more than men on medical expenses?

WHO recommends dropping component of many flu vaccines

Senator probes 340B programs at Cleveland Clinic, Bon Secours

Why you shouldn’t ask, “What country has the best health care?”

New clues to why women have higher risk of autoimmune disorders

entertainment

focus

knowledge

Wikipedia